DRMA

0.50954.23%
KD

Kathleen D. Scott

Chief Financial Officer

Ms. Kathleen Dreifuss Scott, also known as Kathy, CFA & CPA, is Independent Director at NKGen Biotech, Inc. since September 2023. She serves as Chief Financial Officer at ARS Pharmaceuticals, Inc. since February 2022. She has been an Independent Director of Dermata Therapeutics, Inc. since August 2021. Ms. Scott had been the Chief Financial Officer of Neurana Pharmaceuticals, Inc.January 2017 to March 2022. Prior to Neurana, Ms. Scott was the Chief Financial Officer of Recros Medica from August 2014 to April 2021, Adigica Health from February 2016 to March 2021, Clarify Medical from August 2014 to December 2016, Oncternal Therapeutics from March 2016 to May 2016, MDRejuvena from August 2014 to August 2016 and BioSurplus from March 2010 to November 2014. Prior to BioSurplus, Ms. Scott was a Partner at RA Capital Advisors, a San Diego private investment bank providing financial advisory services. Ms. Scott spent with RA Capital Advisors, from December 1994 to July 2010, completing billions of dollars of mergers, acquisitions, divestitures and restructurings for a broad range of corporate clients. Ms. Scott started her career as an auditor in Arthur Andersen’s San Diego office, focusing on both public and private clients. Ms. Scott is board chair of the YMCA of San Diego County and is a CPA and CFA charter holder. She served as Director, Senior VP, Secretary and Treasurer at Recros Medica, Inc until, 2021. She previously served as a member of the board of Conatus Pharmaceuticals. Ms. Scott graduated magna cum laude from the University of California, Los Angeles where she earned a B.S. in Economics and Business and was named to membership in Phi Beta Kappa. She is a Certified Public Accountant, a CFA charter holder and a FINRA-registered securities representative.

公司職務